Did You Know...
...that in 1800 ether was first used by partyers as a fun diversion? Sniffing the gas led to hilarious and raucous laughter as people watched each other become more and more intoxicated and silly. Several doctors independently realized the value ether would have to anesthetize surgery patients. Of those who claimed rights to the "discovery," none had a happy ending. One had a seizure and died defending his rights. Another spent his life in an asylum because he had been denied acclaim. A third became addicted to chloroform and, in a New York City jail, he soaked a cloth in the drug, severed an artery and bled to death.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7378234 | Method for isolating hepatitis C virus peptides Described is a method for isolating Hepatitis C Virus peptides (HPs) which have a binding capacity to a MHC/HLA molecule or a complex comprising said HCV-peptide and said MHC/HLA molecule characterized by the following steps: —providing a pool of HCV-peptide, said... | 05/27/2008 |
| 7037707 | Method for generating influenza viruses and vaccines The present invention is based on the discovery that a high titer reassortant influenza virus is produced in mammalian cell culture by replacing the NS gene of the A/PuertoRico/3/24 master strain with the NS gene of the A/England/1/53 strain. The invention provides ... | 05/02/2006 |
| 6943233 | Cyclic peptides and aids vaccines Cyclic peptides which comprise, as a constituent chain or chains thereof, one or two amino acid sequences selected from the amino acid sequence Asn-Val-Ser-Glu-Ala-Asp-Asp-Arg-Tyr-Ile and the amino acid sequence Arg-Ser-Gln-Lys-Glu-Gly-Leu-His-Tyr-Thr, and AIDS vacc... | 09/13/2005 |
| 6406705 | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid ad... | 06/18/2002 |
| 6344314 | Determined DNA sequenced derived from a papillomavirus genome, their uses for in vitro diagnostic purposes and the production of antigenic compositions The invention concerns DNA fragments derived from the genomic DNA of HPV-33. These fragments are selected from the group of fragments extending between the nucleotide extremities defined hereafter in relation to the nucleotide-numbering in FIGS. 1a and 1b... | 02/05/2002 |
| 6297357 | prb2/p130 peptide inhibitors of cdk2 kinase activity The present invention provides peptides of pRb2/p130 or mutants or fragments thereof which inhibit cdk2 kinase activity. Method of inhibiting cdk2 kinase activity in cells with these peptides are also provided.... | 10/02/2001 |
| 6221577 | Seroreactive regions on HPV 16-proteins E1 and E2 The invention relates to seroreactive regions on protein E1 and E2 of human papillomavirus (HPV) 16. The application also relates to a vaccine which contains such peptides which contain the seroreactive regions. The invention likewise embraces composition... | 04/24/2001 |
| 6218364 | Fluorinated neurokinin A antagonists Peptide derivatives which are antagonists of neurokinin A. The derivatives have a modified peptide bond having a reduced amide and a fluorinated alkyl attached to the nitrogen atom of the modified peptide bond. For example, Asp-Ser-Phe-Val-Gly-Leu.PSI.[CH... | 04/17/2001 |
| 6171592 | Equine rhinovirus 1 proteins Equine rhinovirus 1 (ERhV1) is a respiratory pathogen of horses which has an uncertain taxonomic status. The nucleotide sequence of the ERhV1 genome and amino acid sequence have been substantially determined (FIG. 2). The predicted polyprotein was encoded... | 01/09/2001 |
| 6120989 | Isolated human cytomegalovirus polypeptides and uses thereof Diagnostically relevant polypeptides and fusion proteins comprising an amino acid sequence which originates from cytomegalovirus and corresponds to a region of the major DNA-binding protein or of the C-terminal region of the tegument protein pp150 fused w... | 09/19/2000 |
| 6010700 | Polypeptides p57 or p9.5 of Borna disease virus and their use for diagnosis and immunization The invention involves polypeptides which correspond to amino acid sequences of protein p57 or protein p9.5 of Borna disease virus. These polypeptides, as well as DNA and RNA fragments are used in test kits and vaccines.... | 01/04/2000 |
| 6010704 | Polypeptides and antibodies characteristic of papillomavirus, and diagnostic procedures and vaccines making use of them The present invention provides papillomavirus DNA, and more particularly DNA probes derived from papillomavirus. The present invention also provides procedures for the use of DNA derived from papillomavirus in the in vitro diagnosis of papillomavirus infe... | 01/04/2000 |
| 5989804 | E6 binding proteins E6-BP polypeptides, nucleic acids encoding E6-BP polypeptides, and uses thereof.... | 11/23/1999 |
| 5989548 | Peptide-based composition against papillomavirus infection Pharmaceutical compositions comprising an antigenic amount of peptides derived from the L1 and L2 OFR's of human papillomavirus type 16 coupled to a carrier or in multimer form.... | 11/23/1999 |
| 5990276 | Synthetic inhibitors of hepatitis C virus NS3 protease An inhibitor of the HCV NS3 protease. The inhibitor is a subsequence of a substrate of the NS3 protease or a subsequence of the NS4A cofactor. Another inhibitor of the present invention contains a subsequence of a substrate linked to a subsequences of the... | 11/23/1999 |
| 5871740 | Methods of using poxvirus p35 as a chemokine inhibitor and compositions therefore A protein designated p35 binds to a number of the chemotaxis-stimulating cytokines known as chemokines. p35 may be used to treat conditions that are mediated by chemokines, such as inflammation. p35 is a secreted protein that can be purified from the cult... | 02/16/1999 |
| 5788969 | Peptides for inducing cytotoxic T lymphocyte responses hepatitis B virus Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV envelope, and are particularly useful in treating or preventing HBV infecti... | 08/04/1998 |
| 5707629 | Immunogenic composition against equine herpesvirus type 1 The present invention is directed to a gene encoding an envelope glycoprotein of equine herpesvirus type 1 (EHV-1), the glycoprotein D (gD) gene, its gene product and antibodies directed against gD polypeptides. The envelope glycoproteins of herpesvirus a... | 01/13/1998 |
| 5688511 | Cellular protein TDP-43 and regulation of HIV-1 gene expression Compositions including a polypeptide or nucleic acid sequence encoding a polypeptide that binds TAR DNA (particularly the region -18 to +28 of HIV-LTR DNA) and that does not bind to TAR RNA (particularly the region +1 to +80 of the TAR RNA) are disclosed.... | 11/18/1997 |
| 5672684 | Recombinant human rotavirus VP7 serotype 4 An isolated gene encoding all or part of the VP7 protein of human rotavirus serotype 4 is claimed. Also claimed in a DNA transfer vector which contains the gene or a portion or sub-unit and a host cell contg. the DNA transfer vector.... | 09/30/1997 |
| 5622703 | Immunodominant sites of HTLV-I envelope protein The invention relates to peptides representing CTL epitopes from the HTLV-I envelope protein. The invention further relates to compositions, comprising the peptides, for priming a T-cell response in a subject. Furthermore, methods for priming a T-cell res... | 04/22/1997 |
| 5601973 | Seroreactive regions on HPV 16 proteins E1 and E2 The invention relates to seroreactive regions on proteins E1 and E2 of human papillomavirus (HPV) 16. The application also relates to a vaccine which contains such peptides which contain the seroreactive regions. The invention likewise embraces compositions fo... | 02/11/1997 |
| 5595884 | Papillomavirus E2 transactivation repressor proteins and DNA This invention relates to E2 trans-activation repressors which interfere with normal functioning of the native full-length E2 transcriptional activation protein of the papillomavirus. This invention also relates to DNA sequences and recombinant DNA molecu... | 01/21/1997 |
| 5595739 | Hepatitis B virus mutants, reagents and methods for detection Mutant Hepatitis B Virus (HBV) nucleic acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HBV nucleic acid sequences, HBV immunogenic particles, and a method for producing antibodies to HBV. Also provided ar... | 01/21/1997 |
| 5574132 | Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV) This invention relates to novel peptides and mixtures thereof useful for detecting HCV infections. These peptides are also useful as active ingredients in vaccines against HCV infection.... | 11/12/1996 |
| 5532340 | Tumor suppressor protein PRB2, related gene products, and DNA encoding therefor The invention provides a tumor suppressor protein of the retinoblastoma family (pRb2) which binds to the E1A transforming domain and to DNA encoding for the pRb2 protein.... | 07/02/1996 |
| 5397695 | Attachment of compounds to polymeric particles using carbamoylonium compounds and a kit containing same Useful materials for diagnostic tests, affinity chromatography, enzymatic reactions and immunoassays are prepared by covalently attaching reactive compounds containing reactive amino or sulfhydryl groups to polymeric particles having pendant carboxyl grou... | 03/14/1995 |
| 5378814 | Hepatitis delta viral polypeptides The entire genome of the hepatitis D virus has been shown to be a circular single-stranded RNA of 1679 bases. Several open reading frames in both the genomic and complementary strands indicate possible protein products. The products encoded in one open re... | 01/03/1995 |
| 5378805 | Immunoreactive HTLV-I/II ENV and POL peptides The present invention relates a peptide having specific immunoreactivity to antibodies to HTLV-I, HTLV-II, or combinations thereof comprising a peptide selected from the group consisting of: Env-1 (HTLV-I; a.a 191-214)LPHSNLDHILEPSIPWKSKLLTLV, Env-2 (HTLV-II; ... | 01/03/1995 |
| 5359039 | Isolated poxvirus A53R-equivalent tumor necrosis factor antagonists Isolated viral proteins, and pharmaceutical compositions made therefrom, are disclosed which are capable of binding to Tumor Necrosis Factor, thereby functioning as Tumor Necrosis Factor antagonists. Also disclosed are processes for preparing isolated vir... | 10/25/1994 |
| 5350671 | HCV immunoassays employing C domain antigens Immunoassays for the detection of antibodies to HCV are provided which employ "C" domain antigens. Immunoassay kits comprising such antigens are also provided.... | 09/27/1994 |
| 5321124 | Art (rev) protein of human T-cell leukemia virus A gene and gene product that regulates the expression of the capsidal envelope genes of HTLV-III/LAV and that can be used to regulate the expression of heterologous (non-viral) genes as well is disclosed. This art gene consists of two exons and can be use... | 06/14/1994 |
| 5219990 | Papillomavirus E2 trans-activation repressors This invention relates to E2 trans-activation repressors which interfere with normal functioning of the native full-length E2 transcriptional activation protein of the papillomavirus. Native full-length E2 trans-activation protein activates transcription ... | 06/15/1993 |
| 5198536 | Peptides comprising an immunogenic site of poliovirus and DNAs containing nucleotide sequences coding for these peptides The invention relates to a DNA fragment containing at the most 315 pairs of nucleotides coding for a peptide which can be recognized by antibodies acting both against the "C" and "D" particles of the same poliovirus and against the VP-1 structural polypep... | 03/30/1993 |
| 5175098 | Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to HIV Immunologically reactive gag proteins of LAV are expresesed in bacterial cells. The gag proteins are encoded by a recombinant plasmid containing procaryotic transcriptional and translational signals for expression, followed downstream by a DNA sequence co... | 12/29/1992 |
| 5175097 | Expression and diagnostic use of GAG-1 encoded peptides which are immunologically reactive with antibodies to HIV Immunologically reactive gag proteins of LAV/HTLV-III are expressed in bacterial cells. The gag proteins are encoded by a recombinant plasmid containing procaryotic transcriptional and translational signals for expression, followed downstream by a DNA seq... | 12/29/1992 |
| 5157110 | Synthetic, anti-complement protein A substantially pure, synthetic protein possessing anti-complement property and a DNA sequence encoding said protein are described.... | 10/20/1992 |
| 5026686 | Antiviral peptides Novel antiviral peptides are disclosed which have a sequence of about 4 to 10 amino acids and which are substantially identical to a small portion of the cytoplasmic domain of a glycoprotein in a virus that contains a lipid-bilayer in its structure.... | 06/25/1991 |
| 4870013 | SV40 early and RSV promoters useful in saccharomyces expression Expression vectors containing coding sequences under the control of SV40 early and RSV promoters are disclosed as useful in producing proteins in saccharomyces yeasts. Construction of such vectors, and their use in yeast transformations are described.... | 09/26/1989 |
| 4870023 | Recombinant baculovirus occlusion bodies in vaccines and biological insecticides The present invention is directed to recombinant baculoviruses which encode fusion polyhedrin proteins capable of forming occlusion bodies containing foreign peptides. The recombinant baculoviruses of the invention are formed by insertion into or replacem... | 09/26/1989 |
